AMP Stock Analysis: Amplifon S.p.A | MI
Medical Distribution | MI, Italy | Market Cap: 3.443m EUR | 12M Return: -10.5% | IT0004056880 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 14.3M
EPS Trend: -71.9%
Qual. Beats: 0
Rev. Trend: 81.4%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Amplifon S.p.A. is an Italy-based global distributor of hearing solutions and customized hearing devices, operating across Europe, the Middle East, Africa, the Americas, and the Asia Pacific. The company complements its product offering with the Ampli-care audiological care platform and the Amplifon App, which allows users to manage device functions from a smartphone, as well as proprietary product lines such as Ampli-power and Ampli-mini hearing devices. Founded in 1950 and headquartered in Milan, Amplifon is classified within the Health Care Distributors sub-industry and relies on a retail-clinic-driven distribution model, selling hearing aids primarily through its own network of branded stores and licensed specialists rather than through third-party retail channels. The hearing care distribution sector tends to benefit from demographic aging in developed markets, which is a structural driver of demand for hearing aids and related audiology services.
- Aging demographics drive sustained hearing aid demand across core European markets
- US OTC hearing aid regulation threatens market share and pricing power
- Americas and APAC expansion accelerates following GAES integration
| Net Income: 72.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA 1.30 > 1.0 |
| NWC/Revenue: -12.41% < 20% (prev -17.99%; Δ 5.58% < -1%) |
| CFO/TA 0.06 > 3% & CFO 205.4m > Net Income 72.3m |
| Net Debt (849.3m) to EBITDA (509.4m): 1.67 < 3 |
| Current Ratio: 0.60 > 1.5 & < 3 |
| Outstanding Shares: last quarter (271.7m) vs 12m ago 20.01% < -2% |
| Gross Margin: 8.59% > 18% (prev 56.45%; Δ -47.86% > 0.5%) |
| Asset Turnover: 64.35% > 50% (prev 62.59%; Δ 1.76% > 0%) |
| Interest Coverage Ratio: 3.42 > 6 (EBIT TTM 202.1m / Interest Expense TTM 59.1m) |
| A: -0.08 (Total Current Assets 440.2m - Total Current Liabilities 738.2m) / Total Assets 3.60b |
| B: 0.30 (Retained Earnings 1.08b / Total Assets 3.60b) |
| C: 0.05 (EBIT TTM 202.1m / Avg Total Assets 3.73b) |
| D: 0.73 (Book Value of Equity 1.51b / Total Liabilities 2.09b) |
| Altman-Z'' = 1.56 = BB |
| DSRI: 1.08 (Receivables 360.4m/335.0m, Revenue 2.40b/2.42b) |
| GMI: 6.57 (GM 56.45% / 8.59%) |
| AQI: 1.08 (AQ_t 0.69 / AQ_t-1 0.64) |
| SGI: 0.99 (Revenue 2.40b / 2.42b) |
| TATA: -0.04 (NI 72.3m - CFO 205.4m) / TA 3.60b) |
| Beneish M = 2.13 (Cap -4..+1) = D |
As of October 31, 2026, the stock is trading at EUR 13.07 with a total of 1,498,060 shares traded. Over the past week, the price has changed by +1.32%, over one month by +9.24%, over three months by +12.73% and over the past year by -10.47%.
Current recommended Stop Loss: 12.60 (which is 3.6% or 1.5 ATR below the current price).
Amplifon S.p.A has no consensus analysts rating.
P/E Trailing = 41.7903
P/E Forward = 14.8368
P/S = 1.4339
P/B = 2.2788
P/EG = 0.4234
Revenue TTM = 2.40b EUR
EBIT TTM = 202.1m EUR
EBITDA TTM = 509.4m EUR
Long Term Debt = 567.8m EUR (from longTermDebt, last quarter)
Short Term Debt = 25.7m EUR (from shortTermDebt, last quarter)
Debt = 1.56b EUR (from shortLongTermDebtTotal, last quarter) + Leases 483.9m
Net Debt = 849.3m EUR (calculated: Debt 1.56b - CCE 712.8m)
Enterprise Value = 4.29b EUR (3.44b + Debt 1.56b - CCE 712.8m)
Interest Coverage Ratio = 3.42 (Ebit TTM 202.1m / Interest Expense TTM 59.1m)
EV/FCF = 12.50x (Enterprise Value 4.29b / FCF TTM 343.3m)
FCF Yield = 8.00% (FCF TTM 343.3m / Enterprise Value 4.29b)
FCF Margin = 14.30% (FCF TTM 343.3m / Revenue TTM 2.40b)
Net Margin = 3.01% (Net Income TTM 72.3m / Revenue TTM 2.40b)
Gross Margin = 8.59% ((Revenue TTM 2.40b - Cost of Revenue TTM 2.19b) / Revenue TTM)
Gross Margin QoQ = 11.17% (prev 11.02%)
Tobins Q-Ratio = 1.19 (Enterprise Value 4.29b / Total Assets 3.60b)
Interest Expense / Debt = 3.79% (Interest Expense 59.1m / Debt 1.56b)
Taxrate = 34.10% (37.5m / 110.0m)
NOPAT = 133.2m (EBIT 202.1m * (1 - 34.10%))
Current Ratio = 0.60 (Total Current Assets 440.2m / Total Current Liabilities 738.2m)
Debt / Equity = 1.03 (Debt 1.56b / totalStockholderEquity, last quarter 1.51b)
Debt / EBITDA = 1.67 (Net Debt 849.3m / EBITDA 509.4m)
Debt / FCF = 2.47 (Net Debt 849.3m / FCF TTM 343.3m)
Total Stockholder Equity = 1.14b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.94% (Net Income 72.3m / Total Assets 3.60b)
RoE = 6.34% (Net Income TTM 72.3m / Total Stockholder Equity 1.14b)
RoCE = 11.84% (EBIT 202.1m / Capital Employed (Equity 1.14b + L.T.Debt 567.8m))
RoIC = 4.81% (NOPAT 133.2m / Invested Capital 2.77b)
WACC = 7.18% (E(3.44b)/V(5.00b) * Re(9.31%) + D(1.56b)/V(5.00b) * Rd(3.79%) * (1-Tc(0.34)))
Discount Rate = 9.31% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 49.96 | Cagr: 8.27%
[DCF] Terminal Value 76.42% ; FCFF base≈333.3m ; Y1≈356.4m ; Y5≈428.3m
[DCF] Fair Price = 21.55 (EV 6.58b - Net Debt 849.3m = Equity 5.73b / Shares 265.7m; r=8.35% [WACC [floored]]; 5y FCF grow 7.86% → 2.50% )
EPS Correlation: -71.86 | EPS CAGR: -7.21% | SUE: 0.19 | # QB: 0
Revenue Correlation: 81.40 | Revenue CAGR: 2.68% | SUE: -0.02 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.08 | Chg30d=-25.27% | Revisions=-25% | Analysts=4
EPS current Year (2026-12-31): EPS=0.72 | Chg30d=+0.14% | Revisions=-38% | GrowthEPS=+0.8% | GrowthRev=+1.5%
EPS next Year (2027-12-31): EPS=0.90 | Chg30d=+1.84% | Revisions=+0% | GrowthEPS=+24.4% | GrowthRev=+44.0%
[Analyst] Revisions Ratio: -31% (up=3, down=7)